SynthesisFrontiers in neurology
Systematic review and meta-analysis on the efficacy and safety of rimegepant for migraine.
Synthesis in Frontiers in neurology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Migraine is a prevalent neurological condition, affecting approximately 14% of the population, and is a leading cause of disability. Conventional treatments may have limited efficacy and tolerability limitations in clinical practice. Rimegepant is approved for the dual indications of managing acute migraine episodes and preventing migraine attacks. Therefore, we sought to evaluate the efficacy and safety of rimegepant in migraine treatment. Method: A systematic search of public databases from their inception until February 2025 was conducted to identify randomized controlled trials for evaluating the efficacy of rimegepant in migraine treatment. The overall estimate was derived using the 95% confidence interval (CI) and risk ratio (RR) in a random-effects model. GRADEprofiler was employed to assess the quality of evidence. The Cochrane Collaboration was utilized to evaluate the risk of bias. Results: Our investigation reviewed 5 studies, which included 2,715 individuals treated with rimegepant and 2,850 control participants. Patients treated with rimegepant had statistically significant pain relief (RR = 1.34; 95% CI 1.27-1.41; Conclusion: Our findings suggest that rimegepant may be effective and generally well tolerated for acute migraine treatment. However, the drug did not demonstrate statistical significance for preventing pain relapse within 2-48 h following administration. Given the limitations in the quality and quantity of the included trials, the findings should be confirmed by multicenter, large-sample, randomized controlled trials. Systematic review registration: https://www.crd.york.ac.uk/PROSPERO/view/CRD420251180156, identifier: CRD420251180156.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.